Protective barrier properties of rhinosectan® spray (Containing xyloglucan) on an organotypic 3d airway tissue model (mucilair): Results of an in vitro study

Allergy, Asthma and Clinical Immunology

Volumn 13, Issue 1, 2017, Pages 1-8

  De Servi, Barbara ^a   Ranzini, Francesco ^a   Piqué, Núria ^b  

^a In Vitro Research Laboratories   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Allergy; Barrier properties; Nasal obstruction; Orgatypic 3D airway tissue model (MucilAir); Preventive measures; Rhinitis; Rhinosectan ; Rhinosinusitis; Xyloglucan

Indexed keywords

EID: 85042780951     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/s13223-017-0209-6     Document Type: Article

References (37)

1. Bayard MA, Algra P, Hyman LJ, Donaldson C. Improving your approach to nasal obstruction. J Fam Pract. 2016;65:889–99.
2. World Health Organization. Antimicrobial resistance: global report on surveillance; 2014. http://www.who.int/drugresistance/documents/sur-veillancereport/en/. Accessed 20 Aug 2014.
3. World Health Organization. Global priority list of antibiotic-resistant bac-teria to guide research, discovery, and development of new antibiotics; 2017. http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed March 2017.
4. Harris AM, Hicks LA, Qaseem A, High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164:425–34.
5. Libman H, Brockmeyer DM, Gold HS. Should we prescribe antibiotics to this patient with persistent upper respiratory symptoms? Grand Rounds Discussion from Beth Israel Deaconess Medical Center. Ann Intern Med. 2017;166:201–8.
6. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S. Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revi-sion. J allergy Clin Immunol. 2017. doi:10.1016/j.jaci.2017.03.050.
7. Ojeda P, Piqué N, Alonso A, Delgado J, Feo F, Igea JM, et al. A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study). Allergy Asthma Clin Immunol. 2013;9:32.
8. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–76.
9. Andersson M, Greiff L, Ojeda P, Wollmer P. Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review. Curr Med Res Opin. 2014;30:1131–7.
10. Allegrini A, Pavone D, Carluccio F. A randomized controlled trial compar-ing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis. Curr Med Res Opin. 2017:1–9. doi:10.1080/03007995.201 7.1341402 (Epub ahead of print).
11. Mattila P, Joenväärä S, Renkonen J, Toppila-Salmi S, Renkonen R. Allergy as an epithelial barrier disease. Clin Transl Allergy. 2011;1:5.
12. Steelant B, Farré R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137:1043–1053. e1–5.
13. Steelant B, Seys SF, Boeckxstaens G, Akdis CA, Ceupeens JL, Hellings PW. Restoring airway epitelial barrier dysfunction: a new therapeutic challenge in allergic airway disease. Rhinology. 2016;54:195–205.
14. Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi J, et al. Regulation of tight junctions in upper airway epithelium. Biomed Res Int. 2013;2013:947072.
15. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012;130(1087–1096):e10.
16. Fukuoka A, Matsushita K, Morikawa T, Takano H. Yoshimoto T1. Diesel exhaust particles exacerbate allergic rhinitis in mice by disrupting the nasal epithelial barrier. Clin Exp Allergy. 2016;46:142–52.
17. Åberg N, Dahl Å, Benson M. A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load. Pediatr Allergy Immunol. 2011;22:594–9.
18. Åberg N, Ospanova ST, Nikitin NP, Emberlin J, Dahl Å. A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy: a double-blind, randomized, placebo-controlled, parallel-group study. Int Arch Allergy Immunol. 2014;163:313–8.
19. Andersson M, Greiff L, Wollmer P. Effects of a topical microemul-sion in house dust mite allergic rhinitis. Basic Clin Pharmacol Toxicol. 2011;108:146–8.
20. Böhm M, Avgitidou G, El Hassan E, Mösges R. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivi-tis. Eur Arch Otorhinolaryngol. 2012;269:495–502.
21. De Servi B, Ranzini F, Piqué N. Effect of Utipro(®) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study. Future Microbiol. 2016;11:651–8.
22. Pleșea Condratovici C, Bacarea V, Piqué N. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial. Gastroenterol Res Pract. 2016;2016:6874207.
23. Gnessi L, Bacarea V, Marusteri M, Piqué N. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015;15:153.
24. García-Larrosa A, Alexe O. Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of urinary tract infection: a randomized controlled trial. Clin Microbiol. 2016;5:1.
25. Salvatorelli N, García-Larrosa A, Allegrini A, Pavone D. A new approach to the treatment of uncomplicated cystitis: results of a randomized placebo-controlled clinical trial. Urol Int. 2016;97:347–51.
26. BéruBé K, Aufderheide M, Breheny D, Clothier R, Combes R, Duffin R, et al. In vitro models of inhalation toxicity and disease The report of a FRAME workshop. Altern Lab Anim. 2009;37:89–141.
27. Iskandar AR, Xiang Y, Frentzel S, Talikka M, Leroy P, Kuehn D, et al. Impact assessment of cigarette smoke exposure on organotypic bronchial epithelial tissue cultures: a comparison of mono-culture and coculture model containing fibroblasts. Toxicol Sci. 2015;147:207–21.
28. Farré R, Vicario M. Abnormal barrier function in gastrointestinal disorders. Handb Exp Pharmacol. 2017;239:193–217.
29. Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol. 2010;88:257–68.
30. Godoy L. Allergic inflammation: where epithelial function interacts with immune response in atopic diseases. Drug News Perspect. 2009;22:233–6.
31. Hammad H, Lambrecht BN. Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses. Allergy. 2011;66:579–87.
32. Broide DH. Allergic rhinitis: pathophysiology. Allergy Asthma Proc. 2010;31:370–4.
33. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol. 2010;125:S24–32.
34. Tsou YA, Tung YT, Wu TF, Chang GR, Chen HC, Lin CD, et al. Lactoferrin interacts with SPLUNC1 to attenuate lipopolysaccharide-induced inflammation of human nasal epithelial cells via down-regulated MEK1/2-MAPK signaling. Biochem Cell Biol. 2017. doi:10.1139/bcb-2016-0047.
35. Felinski EA, Cox AE, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp Eye Res. 2008;86:867–78.
36. Kielgast F, Schmidt H, Braubach P, Winkelmann VE, Thompson KE, Frick M, Dietl P, et al. Glucocorticoids regulate tight junction permeability of lung epithelia by modulating claudin 8. Am J Respir Cell Mol Biol. 2016;54:707–17.
37. Cotovio J, Grandidier MH, Portes P, Roquet R, Rubinstenn G. The in virtro skin irritation of chemicals: optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process. Altern Lab Anim. 2005;33:329–49.